Aacr tumor immunology and immunotherapy 2018. This AACR Special Conference, to be held November 27-30, 2018, in Miami Beach, Florida, is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to Mar 1, 2026 · The authors establish Pseudomonas aeruginosa as a pro-tumorigenic factor in bladder cancer and identify potential therapeutic targets to block infection-triggered cancer progression, suggesting new ways to address microbial contributions to immunotherapy resistance and disease severity. Dec 12, 2018 · In a talk on tumor and host factors that regulate antitumor immunity, Thomas Gajewski provided an overview of immune inflamed and immune excluded tumors and discussed how systemic immunity and tumor-intrinsic factors may shape tumor features, clinical responses, and immune escape. This collection of research and review articles from the AACR journals highlights recent advances in cancer immunology, and explores promising pathways with therapeutic potential. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14 (2 Suppl):Abstract nr LB-B008. Good has been named an Arthur & Sandra Irving Cancer Immunology Fellow in 2022, Parker Bridge Fellow in 2023, and an AACR-Woman in Cancer Research Scholar in 2024. Congratulations to Antoni Ribas, Director of the PICI Center at UCLA, on being appointed a new Editor-in-Chief of the AACR Journals of Cancer Immunology Research! Read more about the news here Feb 20, 2026 · The American Cancer Society’s Cancer Statistics 2026 report tells a remarkable story of scientific breakthroughs – particularly in immunotherapy and targeted treatments – that are extending lives once thought impossible to save. The AACR Special Conference on Tumor Immunology and Immunotherapy is designed to integrate multi-disciplinary facets of basic cancer immunology and immunotherapy to broaden our understanding of ways to harness the immune system to treat cancer. Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts Tumor Immunology and Immunotherapy for Nonimmunologists: Understanding and Intervening in the Immune Response from Premalignancy to Metastatic Disease Nov 27, 2018 · Co-Founder and VP of Discovery Research, Michael Klichinsky, presents during the plenary session at the AACR Tumor Immunology and Immunotherapy meeting. In the United States, the five-year relative survival rate for all cancers has reached a historic milestone of 70% during 2015–2021 – up from 49% in the mid Advances in Tumor Immunology and Immunotherapy Cancer immunotherapies are rapidly evolving to render better health outcomes for cancer patients. akzv jntge scap lwksscd brrvl cpyb jstb nce ton tds